Good morning :)
$
₹
Gilead Sciences Inc

Gilead Sciences Inc

GILD

NASDAQ
Asset Logo

Gilead Sciences Inc

GILD

NASDAQ
$146.431.88% (+2.71)
$
₹
$146.431.88% (+2.71)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - General

Large Cap

With a market cap of $178.2B the stock is ranked 93

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

15.06
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.64
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.13
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-10.63%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.22%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 30 analysts' reports

Buy
19 analysts
Hold
11 analysts
Sell
0 analyst

Analysts expect a +8.02% price upside over the next year

Current Price$146.43
Target Price$158.14

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.42
72.42
1Y Return
19.00%
19.00%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.42
23.42
1Y Return
40.02%
40.02%
Buy Reco %
46.87
46.87
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.03
30.03
1Y Return
32.12%
32.12%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.34
19.34
1Y Return
38.79%
38.79%
Buy Reco %
76.00
76.00
argenx NV ADR
ARGX
argenx NV ADR
P/E Ratio
37.55
37.55
1Y Return
30.88%
30.88%
Buy Reco %
95.45
95.45

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Gilead Sciences Inc -15.062.13
AbbVie Inc72.4250.450.52
Amgen Inc23.4217.452.27

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

7.7
3
7.9
2.1
6.9
2
7.8
-10.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue6.686.957.547.566.667.087.767.926.967.80
Net Income-4.171.611.251.781.311.963.052.182.02-10.49
Net Profit Margin-62.36%23.21%16.60%23.55%19.72%27.67%39.28%27.54%29.03%-134.51%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. Gilead Sciences Inc (GILD) share price today is $146.43 as of September 15, 2026 at 1:30 AM IST. The stock touched a day high of $146.64 and a day low of $144.11.

  2. Gilead Sciences Inc stock trades on NASDAQ under the ticker symbol GILD.

  3. Gilead Sciences Inc's market capitalization is $178.2B as of September 15, 2026 at 1:30 AM IST.

  4. Gilead Sciences Inc's price-to-earnings (P/E) ratio is N/A as of September 14, 2026.

  5. Gilead Sciences Inc's price-to-book (P/B) ratio is 15.06 as of September 14, 2026.

  6. Yes, Gilead Sciences Inc pays a dividend, with a current dividend yield of 2.22%.

  7. Yes, You can buy Gilead Sciences Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Gilead Sciences Inc shares in three steps: 1. Search Gilead Sciences Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Gilead Sciences Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Gilead Sciences Inc (GILD) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0682 shares at the current price of $146.43.

Loading...